EDITOR'S DESK

  • Sterile Injectable Outsourcing Trends: What Biosimilar Developers Must Know
    Sterile Injectable Outsourcing Trends: What Biosimilar Developers Must Know

    Though a majority of the data points in a recent ISR report on Sterile Manufacturing are not specifically focused around biosimilars, I reached out to the report’s lead author to unpack a handful of findings I thought would be important for those involved in both biologics and biosimilar manufacturing and outsourcing.  

Solving Pharma’s Public Opinion Crisis

Americans' view of the pharma industry is at an all-time low. NSF Health Sciences Global VP Martin Lush says to change that, something radical will have to happen.

Why EU’s New Med Device Regs Matter To Biopharma

Pharma's CMC regulatory affairs staff, R&D leadership, manufacturing, quality and compliance professionals take note: the EU MDR is real, it becomes effective next May, and it brings with it new challenges and regulatory uncertainty for manufacturers of combination products.     

FDA’s Woodcock: Biosimilar Development Promotes Future Of Better Biologics

While some regulators may express skepticism that we’ll see major changes to the clinical component of the biosimilar development pathway, Woodcock’s DIA keynote exemplified what I found to be a strikingly different attitude about the future possibilities for biosimilar development.

Abcentra Chief Looks Beyond The Clinical Horizon

Why Bert Liang, M.D., Ph.D. obsesses over at-scale manufacturing and regulatory challenges from the outset of clinical trials. 

More From Our Editors

GUEST COLUMNISTS

  • Pigeons In The Plant: 10 Real-Life Pharma Facility Blunders (And How To Avoid Them)
    Pigeons In The Plant: 10 Real-Life Pharma Facility Blunders (And How To Avoid Them)

    There are many ways to tackle pharmaceutical facility design, engineering, building, and production, and each plant has its own methods and culture. However, there are situations we have come across where we really scratch our heads and say, “What did they just do, and what were they thinking?” This article describes a series of events or activities that we have seen and, while they are amusing or baffling, they reveal the flaws in our industry.

  • SOP Remediation: When Reinventing The Wheel Is The Best Approach
    SOP Remediation: When Reinventing The Wheel Is The Best Approach

    There is a growing industry focus on standard operating procedure (SOP) remediation. Although outsourcing, mergers, and acquisitions have been in play for the last 20 years, these activities seem to be skyrocketing, which is creating quite a few scenarios that drive the need for SOP remediation.

  • EU5 Biosimilar Adoption: What Can The Past Tell Us About The Future?
    EU5 Biosimilar Adoption: What Can The Past Tell Us About The Future?

    More than 13 years ago, Omnitrope (somatropin) received its approval in Europe on April 14, 2006. Since then, as of June 2019, 57 biosimilars from 15 different molecules have received greenlights, 27 of them in the last five years and 16 in the last year and a half. This acceleration is driven by the increasing need to generate savings that help keep pharmaceutical budgets under control. According to data from the consulting firm Fiercepharma, drugs approved in 2019 will generate sales of more than $20 billion in 2024.

  • What Can We Learn From Compounding Pharmacies Producing Small Parenteral Batches?
    What Can We Learn From Compounding Pharmacies Producing Small Parenteral Batches?

    Does the pharmaceutical industry want to sit on the sidelines while its products are being manipulated and modified — a danger? Or will the industry provide its products in a manner or with the tools that will enable compounding pharmacies to succeed in delivering a safe and effective drug to the patient — an opportunity?

  • 4 Tips For Successful Collaboration With Your EU Qualified Person (QP)
    4 Tips For Successful Collaboration With Your EU Qualified Person (QP)

    Qualified Persons (QPs) are responsible for the certification of clinical trial materials in the EU and therefore are an essential link in U.S. sponsors’ supply chains. Indeed, engaging QPs well before the clinical trial material needs to be certified not only assures a smooth release process and trial start-up but mitigates pitfalls associated with unanticipated technical, quality, and regulatory challenges.

  • Debunking The Top 3 Myths About Quality By Design (QbD)
    Debunking The Top 3 Myths About Quality By Design (QbD)

    Pharmaceutical quality by design (QbD) and quality risk management (QRM) principles have become mainstays in pharmaceutical development. However, several myths are prevalent that prevent wider acceptance of the concepts by smaller firms. The lack of understanding of pertinent quality by design methods prevents smaller firms from benefiting from the majority of what QbD offers.

  • New EMA Requirements On Nitrosamines: What ALL Pharma Needs To Know
    New EMA Requirements On Nitrosamines: What ALL Pharma Needs To Know

    The EMA recently issued two new publications containing information on nitrosamines for marketing authorization holders (MAHs). Every MAH and manufacturer of chemically synthesized APIs and resulting drug products should carefully read the new EMA expectations on potential nitrosamine contamination.

  • Will Authorized Biologics Disrupt The Market For Biosimilars?
    Will Authorized Biologics Disrupt The Market For Biosimilars?

    Many of the doomsday scenario predictions for biosimilar competition if authorized biologics were to enter the space prematurely assume mainstream development and adoption of authorized biologics by innovator companies in the current market and do not take into consideration the outcomes seen over the past 18 years with authorized small molecule generics.

More From Our Guest Columnists

BIOPROCESSING WHITE PAPERS

  • Cell Therapy Logistics

    Having a sound logistics strategy to ensure that a living drug is delivered to the right patient at the right time, location, and temperature is essential to patient safety and product effectiveness.

  • Flow Chemistry vs Batch Processes

    Chemical development is a time-consuming, expensive, and labor-intensive process. Traditionally, new chemicals are developed using batch processing, which fully relies on versatile and qualified equipment to perform different unit operations. To address these above challenges, continuous flow chemistry technology is currently emerging as an effective tool to conduct chemical synthesis, both at the micro and mesoscale, providing an improved product quality with safe and environmentally conducive process in comparison to traditional batch synthesis.

  • Component Selection: The Key To Your Program Success

    Companies in need of aseptic syringe and vial fill and finish services may find themselves unprepared for selecting the right components and component supplier to meet the needs of their product. A critical process, which can be overlooked or underestimated, thereby jeopardizing clinical or commercial programs.

  • Optimizing Drug Safety And Efficacy Of Complex Next-Generation Biologics

    Learn what challenges exist when developing biologic drugs to be efficacious but safe and how novel analytical techniques, like surface plasmon resonance, can help circumvent these issues and optimize development.

  • A Molecule’s Journey – Break Down Roadblocks To Commercial Success

    A guide for today’s biopharma executives seeking to navigate through the important considerations necessary to successfully build their own cGMP biomanufacturing facility.

More Bioprocessing White Papers

BIOPROCESS ONLINE CONTENT COLLECTIONS

DataIntegrity

 

This free collection of articles is from the Data Integrity In The Life Sciences series, the purpose of which is to highlight contemporary insights and relationships to key quality systems in order to elevate the most important topics and advance improvements in the collective quality culture.

More Content Collections

LIFE SCIENCE INDUSTRY EVENTS

Preparing eCTD Submissions: A Step-By-Step Guide November 19 - 19, 2019
1pm-2:30pm EST, Online Training
Establishing Appropriate Quality Metrics November 21 - 21, 2019
1pm-2:30pm EST, Online Training
Essentials of Disinfectant Efficacy Testing – Ensuring Microbial Control December 12 - 12, 2019
1pm-2:30pm EST, Online Training
More Industry Events

TRAINING COURSES

Preparing eCTD Submissions: A Step-By-Step Guide November 19 - 19, 2019
1pm-2:30pm EST, Online Training
Establishing Appropriate Quality Metrics November 21 - 21, 2019
1pm-2:30pm EST, Online Training
Essentials of Disinfectant Efficacy Testing – Ensuring Microbial Control December 12 - 12, 2019
1pm-2:30pm EST, Online Training
More Upcoming Courses